BridgeBio Pharma Cash Flow Statement
NASDAQ: BBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BridgeBio Pharma free cash flow
In fiscal 2025, BridgeBio Pharma generated -$445.9 million of operating cash flow and spent $1.1 million on capital expenditures. That left free cash flow of -$447.0 million, a free-cash-flow margin of -89.0% of revenue. BridgeBio Pharma returned $48.3 million to shareholders through share repurchases.
Summary generated from market data by MetaCap's automated system. Methodology
BridgeBio Pharma cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -732.94M | -543.35M | -653.25M | -484.65M | -586.45M | -505.49M | -288.58M | -169.45M | -43.83M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 5.43M | 6.08M | 6.49M | 6.77M | 5.84M | 1.46M | 859.00K | — | — |
| Stock-Based Compensation | 133.02M | 95.80M | 108.71M | 91.56M | 99.50M | 58.46M | 21.37M | 6.07M | 1.84M |
| Change in Working Capital | 95.60M | 26.15M | 14.64M | 41.05M | -6.98M | -2.88M | -21.65M | 16.04M | 1.75M |
| Operating Cash Flow | -445.91M | -520.73M | -527.72M | -419.49M | -497.93M | -399.71M | -253.59M | -136.64M | -40.49M |
| Capital Expenditures | -1.10M | -933.00K | -1.31M | -4.82M | -13.25M | -7.52M | -2.64M | -2.18M | -464.00K |
| Investing Cash Flow | -24.49M | 60.78M | 54.03M | 453.15M | -200.83M | -52.99M | -217.25M | -21.04M | -464.00K |
| Dividends Paid | — | — | — | — | — | — | -997.00K | — | -1.15M |
| Share Repurchases | -48.28M | 0 | 0 | 0 | -200.00M | -75.00M | — | — | — |
| Debt Issued | — | 450.00M | 0 | 0 | 456.30M | 0 | 36.94M | 1.00M | 4.00M |
| Debt Repaid | — | -473.42M | 0 | -20.49M | -124.12M | 0 | — | -1.10M | — |
| Financing Cash Flow | 359.29M | 748.46M | 451.54M | -13.13M | 736.45M | 447.19M | 398.79M | 501.55M | 112.98M |
| Net Change in Cash | -111.10M | 288.51M | -22.15M | 20.52M | 37.69M | -5.52M | -72.05M | 343.87M | 72.03M |
| Free Cash Flow | -447.01M | -521.66M | -529.03M | -424.31M | -511.18M | -407.23M | -256.23M | -138.82M | -40.95M |
This table shows 9 annual periods of BridgeBio Pharma's cash flow statement, from FY 2025 back to FY 2017, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BBIO's reporting calendar. What is a cash flow statement?